Prostate Cancer - Results from #1180

Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies. April 4, 2024

Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model. April 4, 2024

Photon vs proton hypofractionation in prostate Cancer: A systematic review and meta-analysis. April 4, 2024

A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database. April 4, 2024

Prostate-Specific Antigen Screening in Smokers: A Comprehensive Analysis Using a National Behavioral Survey. April 4, 2024

Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castrate-Resistant Prostate Cancer Setting: A Systematic Review and Meta-Analysis April 3, 2024

Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. April 3, 2024

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality. April 3, 2024

The Impact of Omitting Contralateral Systematic Biopsy on the Surgical Planning of Patients with a Unilateral Suspicious Lesion on Magnetic Resonance Imaging Undergoing Robot-assisted Radical Prostatectomy for Prostate Cancer. April 3, 2024

Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer. April 3, 2024

Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays. April 3, 2024

Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. April 3, 2024

Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in Men with High-Risk Biochemically Recurrent Prostate Cancer and Prior Radiotherapy: EMBARK Subgroup Analysis April 2, 2024

PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. April 2, 2024

Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study. April 2, 2024

The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective. April 2, 2024

Advances in Radioligand Theranostics in Oncology. April 2, 2024

Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials. April 2, 2024

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. April 1, 2024

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. April 1, 2024

Page 60 of 1438